|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200062676 |
|
最近更新日期: Date of Last Refreshed on: |
2022-08-15 14:50:44 |
|
注册时间: Date of Registration: |
2022-08-15 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于脑区域氧饱和度的脆性骨折老年患者围术期缺铁性贫血治疗策略 |
|
Public title: |
Perioperative management of iron deficiency anemia in elderly patients with brittle fractures based on regional oxygen saturation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于脑区域氧饱和度的脆性骨折老年患者围术期缺铁性贫血治疗策略 |
|
Scientific title: |
Perioperative management of iron deficiency anemia in elderly patients with brittle fractures based on regional oxygen saturation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
曹寅 |
研究负责人: |
杨晓东 |
|
Applicant: |
Cao Yin |
Study leader: |
Yang Xiaodong |
|
申请注册联系人电话: Applicant telephone: |
18057493272 |
研究负责人电话:
Study leader's |
18858091203 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
caojeky@163.com |
研究负责人电子邮件: Study leader's E-mail: |
caojeky@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省宁波市江北区祥北路68号 |
研究负责人通讯地址: |
浙江省宁波市江北区祥北路68号 |
|
Applicant address: |
68 Xiangbei Road, Jiangbei District, Ningbo City, Zhejiang Province, China |
Study leader's address: |
68 Xiangbei Road, Jiangbei District, Ningbo City, Zhejiang Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
宁波市第九医院 |
||
|
Applicant's institution: |
Ningbo Ninth Hospital |
||
|
研究负责人所在单位: |
宁波市第九医院 |
||
|
Affiliation of the Leader: |
Ningbo Ninth Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021LIK07 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
宁波市第九医院伦理委员会 |
||
|
Name of the ethic committee: |
The ethics committee of Ningbo Ninth Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-01-19 00:00:00 | ||
|
伦理委员会联系人: |
马丁莹 |
||
|
Contact Name of the ethic committee: |
Ma Dingying |
||
|
伦理委员会联系地址: |
浙江省宁波市江北区祥北路68号 |
||
|
Contact Address of the ethic committee: |
68 Xiangbei Road, Jiangbei District, Ningbo City, Zhejiang Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
宁波市第九医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ningbo Ninth Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省宁波市江北区祥北路68号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
68 Xiangbei Road, Jiangbei District, Ningbo City, Zhejiang Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
宁波市医学科技计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Ningbo Medical Science and Technology Project |
||||||||||||||||||||||
|
研究疾病: |
缺铁性贫血 |
||||||||||||||||||||||
|
Target disease: |
Iron deficiency anemia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
建立《基于脑区域氧饱和度的围术期缺铁性贫血治疗决策表》。选择本院脆性骨折合并缺铁性贫血的老年患者,以入院时rSO2为基线值,若rSO2≥65%,则将患者“目标Hb浓度”设定为80 g/L;若55%≤rSO2<65%,则将患者“目标Hb浓度”设定为100 g/L;若rSO2<55%,则将则将患者“目标Hb浓度”设定为120 g/L。根据血常规患者实际Hb浓度,可计算出患者需要的铁剂治疗量,再将总剂量分成7份,每两天静脉给予铁剂一次,共治疗14天,这恰好是我院脆性骨折老年患者正常住院天数。 |
||||||||||||||||||||||
|
Objectives of Study: |
To establish the perioperative decision table for the treatment of iron deficiency anemia based on regional oxygen saturation. Elderly patients with brittle fracture complicated with iron deficiency anemia in our hospital were selected. RSO2 at admission was taken as the baseline value. If rSO2≥65%, the "target Hb concentration" of the patients was set as 80 g/L. If 55%≤rSO2 < 65%, the "target Hb concentration" of patients was set as 100 g/L; If rSO2 < 55%, the patient's "target Hb concentration" will be set at 120 g/L. According to the actual Hb concentration of blood routine patients, the amount of iron treatment needed by the patients can be calculated, and then the total dose is divided into 7 parts, and iron treatment is given intravenously every two days for a total of 14 days, which is exactly the normal hospitalization days of elderly patients with brittle fracture in our hospital. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)性别不限,年龄≥60岁;(2)采用静脉铁剂方案治疗IDA;(3)骨折部位为髋部骨折。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) No gender limitation, age ≥60; (2) Intravenous iron regimen for IDA; (3) The fracture site is hip fracture. |
||||||||||||||||||||||
|
排除标准: |
(1)蔗糖铁注射液过敏的患者;(2)选择保守治疗的患者;(3)低磷血症;(4)严重心脑血管疾病;(5)呼吸衰竭;(6)肝肾功能障碍;(7)Ⅰ型或Ⅱ型糖尿病;(8)除IDA外合并有其他类型的贫血。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Patients allergic to iron sucrose injection; (2) patients who chose conservative treatment; (3) hypophosphatemia; (4) serious cardiovascular and cerebrovascular diseases; (5) respiratory failure; (6) liver and kidney dysfunction; (7) Type ⅰ or type ⅱ diabetes mellitus; (8) Other types of anemia in addition to IDA. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-08-01 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-08-01 00:00:00 至 To 2022-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表法 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number table method |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
中国临床试验注册中心 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Chinese Clinical Trial Registry |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case sheet |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |